Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
OtherArticle

Allosteric Modulator KM822 Attenuates Behavioral Actions of Amphetamine in C. elegans through Interactions with the Dopamine Transporter DAT-1

Osama Refai, Shaili Aggarwal, Mary Hongying Cheng, Zayna Gichi, Joseph M Salvino, Ivet Bahar, Randy D Blakely and Ole V Mortensen
Molecular Pharmacology December 14, 2021, MOLPHARM-AR-2021-000400; DOI: https://doi.org/10.1124/molpharm.121.000400
Osama Refai
1Florida Atlantic University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaili Aggarwal
2Drexel University College of Medicine, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Hongying Cheng
3University of Pittsburgh, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zayna Gichi
1Florida Atlantic University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph M Salvino
4Wistar Institute, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivet Bahar
5Computational Biology, School of Medicine, University of Pittsburgh, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ivet Bahar
Randy D Blakely
1Florida Atlantic University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ole V Mortensen
6Drexel University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ole V Mortensen
  • For correspondence: ovm23@drexel.edu
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Aberrant dopamine (DA) signaling is associated with several psychiatric disorders such as bipolar disorder, addiction, and Parkinson's disease, and several medications that target the DA transporter (DAT) can induce or treat these disorders. Biochemical and crystallographic studies demonstrate that the competitive actions of DAT antagonists and substrates, such as cocaine and D-amphetamine (AMPH), rely on interactions with the transporter's substrate binding site. Agents that exhibit noncompetitive, allosteric modulation of DAT remain a significant topic of investigation, owing to their potential therapeutic applications. We previously identified a novel allosteric modulator of human DAT, KM822, that can decrease the affinity of cocaine for DAT and attenuate cocaine-elicited behaviors, though whether DAT is the sole mediator of KM822 actions in vivo is unproven given the large number of potential off-target sites. The function of C. elegans DAT (DAT-1) has been well characterized and used in both genetic and pharmacological studies of psychostimulant action and transporter regulation. Here, we provide in silico and in vitro evidence that the allosteric site engaged by KM822 is conserved between human DAT and DAT-1 and that KM822 interacts with DAT-1. Through a combination of genetic and pharmacological in vivo approaches we provide evidence that the ability of KM822 to diminish the behavioral actions of AMPH arises through its allosteric modulation of DAT-1. More broadly, our findings demonstrate allosteric modulation of DAT as a behavior modifying strategy and suggests that C. elegans can be operationalized to identify and investigate the interactions of DAT allosteric modulators.

Significance Statement We previously demonstrated that the DAT allosteric modulator KM822 decreases cocaine affinity for human DAT. Here, using in silico and in vivo genetic approaches, we extend this finding to interactions with amphetamine (AMPH), demonstrating evolutionary conservation of the DAT allosteric site. In C. elegans, we report that KM822 suppresses AMPH behavioral effects via specific interactions with DAT-1. Our findings reveal C. elegans as a new tool to study allosteric modulation of DAT and its behavioral consequences.

  • addiction
  • Allosterism
  • amphetamine
  • Dopamine
  • Copyright © 2020 American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Molecular Pharmacology: 102 (2)
Molecular Pharmacology
Vol. 102, Issue 2
1 Aug 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Allosteric Modulator KM822 Attenuates Behavioral Actions of Amphetamine in C. elegans through Interactions with the Dopamine Transporter DAT-1
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherArticle

Allosteric DAT modulator suppresses AMPH actions

Osama Refai, Shaili Aggarwal, Mary Hongying Cheng, Zayna Gichi, Joseph M Salvino, Ivet Bahar, Randy D Blakely and Ole V Mortensen
Molecular Pharmacology December 14, 2021, MOLPHARM-AR-2021-000400; DOI: https://doi.org/10.1124/molpharm.121.000400

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherArticle

Allosteric DAT modulator suppresses AMPH actions

Osama Refai, Shaili Aggarwal, Mary Hongying Cheng, Zayna Gichi, Joseph M Salvino, Ivet Bahar, Randy D Blakely and Ole V Mortensen
Molecular Pharmacology December 14, 2021, MOLPHARM-AR-2021-000400; DOI: https://doi.org/10.1124/molpharm.121.000400
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Anti-aromatase activity of exemestane phase II metabolites
  • α-Conotoxin Binding Site on the GABAB Receptor
  • Upacicalcet binds to the amino acid binding site of CaSR
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics